Female steroidsTamoxifene citrate (Nolvadex) injectables cas 54965-24-1 for weight loss
wholesale prices,negotiable
Features Gallery Product Description Request A Quote
Basic Infomation
Place of Origin: Zhejiang,China
Brand Name: Pharma Grade
Certification: ISO,GMP
Model Number: 54965-24-1
High Light:

pharmaceutical grade steroids


muscle gain steroids

Payment & Shipping Terms
Packaging Details: Foil bag or other discreelty package,according the order quantity and different country
Delivery Time: within 24 hours after payment
Payment Terms: Western Union, MoneyGram, T/T,bank transfer,Bitocin
Supply Ability: 1000kg/month
Name: Tamoxifene Citrate
Other Name: Nolvadex
Purity: 99%
Cas: 54965-24-1
Usage: Muscle Growth Steroids
Feature: Natural And Healthy
Product Description

Female steroidsTamoxifene citrate (Nolvadex) injectables cas 54965-24-1 for weight loss


Tamoxifen Citrate, Nolvadex
CAS NO.:10540-29-1
Purity: 99.5%
Molecular Formula: C26H29NO
Molecular Weight: 371.51
White crystalline powder .
Usage:Breast cancer and oophoroma.
Packing: 25kgs drum/ aluminium tin or as required.
Min. order quantity: 10g
Shipment: EMS, DHL, FedEx, TNT
Delivery: safe & timely, around 7days after payment.


Quick Detail:

Female steroidsTamoxifene citrate (Nolvadex)  injectables cas 54965-24-1  for weight loss 0



Product Description:

Chinese name: Tamoxifen
Chinese alias: (Z)-2-[4-(1,2-diphenyl-1-butene)phenoxy]-N,N-dimethylethylamine; nitrogen N-desmethyl tamoxifen hydrochloride Tamoxifen
English name: tamoxifen
English alias: Oncomox; [3H]-Tamoxifen; Soltamox; Crisafeno; trans-2-[1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine;
CAS No.: 10540-29-1
Molecular formula: C26H29NO
Molecular weight: 371.51500
Exact quality: 371.22500
Chemical structure: as shown on the right
PSA: 12.47000
LogP: 5.99610 [2]

Physicochemical properties
Appearance and traits: fine grayish white crystalline powder
Density: 1.042 g/cm3
Melting point: 97-98oC
Flash point: 140oC
Refractive index: 1.582
Storage conditions: 2-8oC vapor pressure: 1.85E-09mmHg at 25°C
Toxicological data
First, the test method: oral
Intake dose: 5600 ug/kg/1W-I
Test object: person-woman
Toxicity type: acute
Toxicity: skin and add-ons - breast cancer II. Test methods: not reported
Intake dose: 200 μg / kg / number
Test object: person-woman
Toxicity type: acute
Toxic effects: 1. Nausea or vomiting
2. Leukopenia
3. Thrombocytopenia III. Test methods: not reported
Intake dose: 5600 ug/kg/2W-I
Test object: person-woman
Toxicity type: acute
Toxicity: Anemia
Fourth, test method: oral intake dose: 4100 mg / kg
Test object: rodent-mouse
Type of toxicity: Acute toxicity: Detailed toxic side effects are not reported other than lethal dose values
Ecological data
The substance may be hazardous to the environment and special attention should be given to the water body.
Molecular structure data
1, molar refractive index: 118.89
2, molar volume (m3 / mol): 356.2
3. Isotonic specific volume (90.2K): 898.14, surface tension (dyne/cm): 40.4
5, polarizability (10-24cm3): 47.13 calculation of chemical data
1. Hydrophobic parameter calculation reference value (XlogP): 7.1
2. Number of hydrogen bond donors: 0
3. Number of hydrogen bond acceptors: 2
4. Number of rotatable chemical bonds: 8
5. Number of tautomers: none
6. Topological molecular polarity surface area 12.5
7. Number of heavy atoms: 28
8. Surface charge: 0
9. Complexity: 463
10. Number of isotope atoms: 0
11. Determine the number of atomic stereocenters: 0
12. Uncertain number of atomic stereocenters: 0
13. Determine the number of chemical bond stereocenters: 1
14. Uncertain chemical bond stereocenter number: 0
15. Number of covalent bond units: 1
Nature and stability
Use and store in accordance with specifications will not be broken down. [3]


Related drug instruction information
Category Name
Primary classification: endocrine system drugs secondary classification: gonad disease medication
English name of the drug

Tamoxifen citrate, tamoxifen citrate, tamoxifen, Novartis, tamoxifen citrate, tamoxifen, tamoxifen, Nolvadex, Tam, TamoxifenCitrate
Pharmaceutical dosage form
1. Tablet: 10 mg; 2. Capsule: 10 mg.
Pharmacological action
For the synthesis of anti-estrogen drugs. It is similar in structure to estrogen. It competes with estradiol for estrogen receptors, forms a stable complex with estrogen receptors, and transports them into the nucleus, preventing the opening of chromosomal genes, thereby inhibiting the growth and development of cancer cells.

After the drug was orally administered with 20 mg, the peak concentration of the blood drug was 4 to 7 hours, which was 0.14 μg/ml. After administration for 4 days or more, a second peak may occur due to intestinal hepatic circulation. The half-life β phase is greater than 7 days, and the alpha phase is 7 to 14 hours. 4 to 10 weeks after administration, the objective signs are improved, and if there is bone metastasis, it is effective for several months. A single dose of antiestrogenic effect lasts for several weeks. The drug is metabolized in the liver. The main metabolites are N-desmethyl tamoxifen and 4-hydroxy tamoxifen, and also have a role in binding to estrogen receptors. Most of the drug is excreted in the form of a conjugate and a small amount is excreted from the urine. The half-life of the parent compound of this product is 5-7 days, and the metabolite nitrogen-desmethyltamoxifen is 14 days. Indication
1. Postoperative adjuvant therapy for breast cancer, for estrogen receptor-positive patients, especially those with a post-menopausal age of 60 years or older. 2. Advanced breast cancer, or relapse after treatment. It has a good effect on skin, lymph node and soft tissue metastasis. Endometrial cancer.


Female steroidsTamoxifene citrate (Nolvadex)  injectables cas 54965-24-1  for weight loss 1


1. Pregnant women and those with thromboembolic diseases. 2. Have a history of deep vein thrombosis. 3. Have a history of pulmonary embolism.
1. Check the visually impaired, liver and kidney dysfunction before use. 2. For patients who are taking this product for a long time and are at risk of thromboembolism, the blood should be checked regularly during treatment. If there is bone metastasis, blood calcium should be checked regularly at the beginning of treatment. Liver function should be tested regularly during long-term treatment with this product for more than 2 years. 3. When abnormal vaginal bleeding occurs, you should see a doctor immediately and have a thorough examination. The drug should be discontinued when there is a lot of vaginal bleeding. 4. Patients treated with this product have an increased risk of endometrial cancer, so a careful gynaecological examination should be performed. 5. The use of this product can appear sudden ovarian functional cysts and menorrhagia and irregular uterine bleeding. Therefore, if you must use this medicine before menopause, you should take anti-gonadotropin drugs at the same time.
Adverse reactions
1. Gastrointestinal reactions: loss of appetite, nausea, vomiting, diarrhea. 2. Secondary anti-estrogen effects: facial flushing, genital itching, menstrual disorders, amenorrhea, increased vaginal discharge, vaginal bleeding. 3. Neuropsychiatric symptoms: headache, dizziness, depression, etc. 4. Long-term application of large doses can cause visual impairment, such as cataracts. 5. Myelosuppression: A small number of patients may have transient white blood cells and thrombocytopenia. 6. Others: rash, hair loss, weight gain, abnormal liver function, etc.



How to make an order :

1. Name what your need ( which product , quantity )
2. Full payment would be done once we come to an agreement on all details .
3. Parcel would be shipped out upon receipt of payment .
4. Info about parcel would be offered ( Photo , tracking number )
5. Finally you would get the parcel in 3~7 days .




Recommended Products
Get in touch with us
Contact Person : Anne
Tel : +8613486829776
Characters Remaining(20/3000)